Pulmonx logo

PulmonxNASDAQ: LUNG

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 October 2020

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$243.64 M
-85%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-68%vs. 3y high
66%vs. sector
-91%vs. 3y high
47%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:18:26 GMT
$6.17-$0.07(-1.12%)

Dividend

No data over the past 3 years
$20.39 M$22.29 M
$20.39 M-$14.14 M

Analysts recommendations

Institutional Ownership

LUNG Latest News

Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
zacks.com30 October 2024 Sentiment: NEUTRAL

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
prnewswire.com09 September 2024 Sentiment: POSITIVE

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Conference on Lung Cancer (WCLC) in San Diego.

Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
globenewswire.com29 August 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024.

Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
globenewswire.com22 August 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
zacks.com31 July 2024 Sentiment: POSITIVE

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago.

Pulmonx Reports Second Quarter 2024 Financial Results
globenewswire.com31 July 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024.

Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
globenewswire.com29 July 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.

Pulmonx: Low Bar For Q2 Earnings
seekingalpha.com21 July 2024 Sentiment: NEUTRAL

New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses.

Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
globenewswire.com10 July 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
zacks.com22 May 2024 Sentiment: NEUTRAL

The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • 1(current)

What type of business is Pulmonx?

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

What sector is Pulmonx in?

Pulmonx is in the Healthcare sector

What industry is Pulmonx in?

Pulmonx is in the Medical Devices industry

What country is Pulmonx from?

Pulmonx is headquartered in United States

When did Pulmonx go public?

Pulmonx initial public offering (IPO) was on 01 October 2020

What is Pulmonx website?

https://pulmonx.com

Is Pulmonx in the S&P 500?

No, Pulmonx is not included in the S&P 500 index

Is Pulmonx in the NASDAQ 100?

No, Pulmonx is not included in the NASDAQ 100 index

Is Pulmonx in the Dow Jones?

No, Pulmonx is not included in the Dow Jones index

When was Pulmonx the previous earnings report?

No data

When does Pulmonx earnings report?

Next earnings report date is not announced yet